Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits by Song, Zhengyu et al.
Glycyrrhizin could reduce ocular hypertension induced by
triamcinolone acetonide in rabbits
Zhengyu Song,1 Yuanyuan Gong,1 Haiyun Liu,1 Qiushi Ren,2 Xiaodong Sun1
1Shanghai First People’s Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, P.R. China; 2Beijing Universitiy,
Beijing, P.R. China
Purpose: To evaluate the hypotensive effects of glycyrrhizin (GL) on a rabbit model of ocular hypertension (OH) induced
by triamcinolone acetonide (TA).
Methods: Forty New Zealand White Rabbits were divided as follows: control (intravitreal injection of sterile saline
solution); GL (intravitreal injection of sterile saline solution, then fed with 25mg GL/day); TA (intravitreal TA injection);
TA+GL (intravitreal TA injection, then fed with GL) and GL+TA (pre-treated with GL for 3 days, then got TA injection
and the following GL treatment). Intraocular pressure (IOP), flash electroretinogram (flash ERG) and flash visual evoked
potential (flash VEP) were measured during the follow-up (28 days). The aqueous humor was analyzed, using 1H-nuclear
magnetic resonance spectroscopy and principal components analysis (PCA).
Results: IOP elevation was observed in the TA group during the follow-up, compared to the controls (p<0.01). The IOP
was decreased in the TA+GL group and the GL+TA group, compared to the TA group (p<0.05). Both in flash ERG and
VEP, the amplitudes were decreased, and the implicit time was prolonged in the TA group, compared to the controls
(p<0.05); and the parameters were improved after intervention of GL, compared to the TA group (p<0.05). PCA results
indicated that TA could affect ocular metabolism (especially the sugar metabolism), and GL could inhibit it.
Conclusions:  The  administration  of  GL  could  suppress  OH  induced  by  TA  in  rabbits,  and  improve  their
electrophysiological parameters. Metabolomics is a useful tool in ophthalmology research. Our results indicate that TA-
induced ocular metabolism changes could be compensated by GL.
Corticosteroid  induced  glaucoma  (CIG)  is  a  kind  of
secondary  open  angle  glaucoma  occurred  in  susceptible
person  after  general  or  topical  administration  of
glucocorticoid  (GC)  [1].  Ticho  et  al.  [2]  found  that
dexamethasone could lead to abnormal accumulation of acid
mucopolysaccharide in the chamber angle. Some researchers
[3-5] reported that 3 alpha, 5 beta-tetrahydrocortisol (steroid
antagonist)  could  lower  the  intraocular  pressure  (IOP)  in
steroid  induced  ocular  hypertension  (OH)  cases.  But  the
pathogenesis of CIG/OH still remains unclear, and the drug
therapy has limited effects. The incidence of CIG/OH has
increased  gradually  by  widely  using  of  triamcinolone
acetonide (TA) and GC-containing eye preparations in recent
years.  It  is  reported  that  30%–62.3%  of  patients  have
experienced  CIG/OH  up  to  24  months  after  intravitreal
injection of TA [6-8]. About 0.3%–3.3% of patients had to
perform anti-glaucomatous surgery or laser therapy (selective
laser trabeculoplasty, etc.) because of uncontrolled OH [7,8].
Even after the surgery, some patients still had permanent loss
of visual acuity and impairment of the visual field [9]. So the
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targeted therapy is urgently needed. New methods, including
anecortave and gene therapy virus (GC-inducible MMP1), are
reported to be effective in animal models [10-12]. However,
those methods are invasive, and may have severe side effects
(endophthalmitis, hemorrhage, etc.).
In  vivo,  there  exists  a  GC  balance,  which  includes
cortisone (no biologic activity)/ cortisol (biologic activity)
[13]. As a low affinity NADP (H)-dependant enzyme with bi-
direction  (11-oxo-reductase  and  dehydrogenase),  11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a tissue-
specific  regulator  of  GCs  [13-15].  Mainly  acting  as  a
reductase in ocular tissue, 11β-HSD1 can transform cortisone
into cortisol, and then cortisol can increase the resistance of
aqueous humor outflow to raise IOP [13,16,17]. So 11β-HSD1
is  regarded  as  a  potent  target  to  regulate  GC  activity.  A
significant reduction (10%–20%) of IOP after the systemic
administration  of  carbenoxolone  (CBX),  a  non-selective
inhibitor of 11β-HSD1 and used to treat digestive ulcer, could
be found in normal volunteers (especially from day 3 to day
7) [16,17]. And Rauz et al. [18] reported those who had a fall
in IOP also demonstrated a change in steroid metabolites
consistent with 11β-HSD1 inhibition. But CBX is out of use
because of severe complications (hypertension, electrolyte
disturbance, etc.). Glycyrrhizin (GL), oral administration to
treat  liver  diseases  (liver  cirrhosis  and  so  on),  can  be
transformed into glycyrrhetinic acid (GA) in vivo [19]. GA
can inhibit 11β-HSD1 in liver and kidney, with little mild
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2056complications  [20,21].  It  was  reported  that  5β-dihydro-
cortisol could enhance the function of cortisol in eye [22], both
GL and CBX can potently inhibit 5β-reductase. But there have
been no studies associated with GL in CIG/OH yet, as far as
we know.
The pathogenesis of CIG/OH still remains unclear and it
may involve many cross-linking cytokines, signaling pathway
and biochemical changes, which are all closely related to the
GC  metabolism.  Metabolomics  (or  metabonomics)  is  a
quantitative  measurement  of  'dynamic  multi-parametric
metabolic responses to pathophysiological stimuli or genetic
modification in living systems' [23,24]. It has been widely
used in the evaluation of drugs (toxicity, effect, mechanism,
and indication). Its major methods include nuclear magnetic
resonance spectroscopy (NMR) and mass spectrometry. NMR
data, combined with multivariate statistical analysis (such as
Principal  components  analysis,  PCA),  is  a  useful  tool  to
investigate  the  pathophysiological  metabolism  [25,26].
However, to the best of our knowledge, there have been no
metabolomics researche associated with CIG/OH or GCs as
yet.
The purpose of this study was to evaluate the ocular
hypotensive effects of GL on a rabbit model of OH induced
by TA, and evaluate the metabolic changes of aqueous humor
using  1H-NMR  spectrum  coupled  with  PCA.  Flash
electroretinogram  (flash  ERG)  and  flash  visual  evoked
potential  (flash  VEP)  was  also  performed  to  estimate  the
visual function.
METHODS
Rabbits: Forty New Zealand White Rabbits (NZWR) of male,
weighing 2.0 to 2.2 kg, were treated in accordance with the
Association  for  Research  in  Vision  and  Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and
Vision Research. Only right eyes were used in this study. To
exclude the presence of any pre-existing abnormalities, the
eyes  were  examined  by  slit-lamp  and  indirect
ophthalmoscope. Blood pressure was recorded every day, and
blood biochemistry test was performed pre and at 1, 7, and 28
days post-injection.
The environment for animal raising was set up as follows:
light (7AM-7PM)/dark (7PM-7AM) cycle; temperature (22–
25  °C);  humidity  (55%–60%);  feeding  two  times  (100  g
standard feed for each time) per day (8AM, 6PM); no limits
to water and activity.
The rabbits were divided into five groups randomly (8
eyes  in  each  group).  In  the  control  group,  the  eyes  were
injected with 0.1 ml sterile saline solution (BSS; Alcon China
Ophthalmic  Product  Company  Ltd.,  Beijing,  China)
intravitreally; in the GL group, the eyes were injected with
0.1 ml BSS intravitreally first, then fed with half Glycyron
Tablets  (Minophagen  Pharmaceutical  Co.,  Ltd.,  Tokyo,
Japan) per feeding in the following 28 days; in the TA group,
the eyes were injected with 0.1 ml/4 mg TA (Bristol-Myers
China Squibb Company, Shanghai, China) intravitreally; in
the TA+GL group, the eyes were injected with 0.1 ml/4 mg
TA first, then received the same GL treatment as in the GL
group; in the GL+TA group, the rabbits were fed with GL 3
days before TA injection, then got the same treatment as in
the TA+GL group.
Anesthesia:  Rabbits  were  anesthetized  via  intramuscular
injection of a mixture containing pentobarbital (20 mg/kg
body wt) and ketamine hydrochloride (20 mg/kg body wt)
before the injection, measurement of IOP, testing for flash
ERG and flash VEP, or withdraw of aqueous humor. Topical
anesthesia (2% lidocaine hydrochloride) was administered to
reduce discomfort.
Injection:  Before  TA  injection,  the  drug  was  pretreated
according  to  Bitter  et  al.  [27]  to  remove  preservatives.
Intravitreal TA injection was performed 2.0 mm posterior to
the  limbus  in  the  superotemporal  quadrants  under
visualization, using a 27 G needle. And after the injection, the
port  was  pressed  with  a  cotton  swab  for  30  s  to  prevent
backflow.
IOP  measurment:  IOP  measurement  was  performed  pre-
injection and at 1, 7, 14, 21, and 28 days post-injection, using
a Tono-pen tonometer (Reichert, Inc., Depew, NY). Each eye
was measured three times and the mean data were recorded.
Flash ERG and flash VEP test: All rabbits were examined by
RETI  port21  (Roland  Retiscan,  Wiesbaden/Brandenburg,
Germany) pre-injection and 7, 14, and 28 days post-injection.
Before test, pupils were fully dilated using a mixture of 0.5%
tropicamide and 0.5% phenylephrine hydrochloride, then the
rabbits were dark-adapted for 30 min before scotopic flash
ERG examination, and light-adapted for 2 h before photopic
flash ERG test (background light intensity was 33 cd). A
unipolar contact lens was placed on the cornea with goniosol
(IOLAB  Corporation,  Claremont,  CA).  The  reference
electrode  (stainless  steel  needle)  was  placed  on  the
subcutaneous space of the forehead, and ground electrode was
clipped to the earlobe. Flash ERG signals were amplified
(×20,000) and filtered (0.3–300 Hz) by differential amplifiers
with a maximum intensity (5.76 cd·s/m2). The implicit time
(IT) and amplitude of flash ERG signals were automatically
measured by a computer program.
Flash VEP signals were recorded using a stainless steel
needle, as the active electrode, inserted under the skin above
the area of the visual cortex midway between two ears. The
reference and ground electrodes were inserted in the ears. The
signals were amplified (×500,000) and filtered (1–100 Hz) by
differential amplifiers. The IT and amplitude of the second
negative  peak  (N2)  were  automatically  measured  by  a
computer program.
Aqueous humor acquirement: After penetrating into anterior
chamber with a 27 G needle in the temporal limbus, 0.1 ml
aqueous humor was acquired pre- and at 1 and 28 days post-
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stored at −30 °C.
NMR spectroscopy: The samples were centrifuged at 12,000×
g  for  10  min  at  4  °C  to  isolate  the  precipitate.  Then  the
supernatants  were  moved  into  5  mm  NMR  tubes,  which
contained 100 μl D2O for field frequency lock. All NMR
spectra were recorded on a Bruker AVANCE III 600 NMR
spectrometer  (Bruker  BioSpin  GmbH,  Rheinstetten,
Germany) operating at 599.69 MHz (1H-frequency) at 25 °C.
Standard one-dimensional PRESAT spectra were acquired
using a single 90° pulse sequence. All spectra were phase- and
baseline-corrected with reference to the methyl peak of lactate
(CH3, 1.33).
Data reduction and pattern recognition: All NMR spectra
were data-reduced to 241 integrated regions of equal width of
0.04 ppm (buckets) corresponding to the region of δ10.0 to
0.4,  by  VNMR  6.1C  software  package  (Varian  Inc.,  Los
Angeles,  CA).  The  remaining  spectral  segments  for  each
NMR  spectrum  were  normalized  to  the  total  sum  of  the
spectral intensity to partially compensate for differences in
concentration  of  the  many  metabolites  in  the  samples.
Subsequently, the normalized integral values were input into
SIMCA-P 10.5 software package (Umetrics, Umeå, Sweden)
as variables and were mean centered for the analysis of PCA.
Data  were  visualized  with  the  principal  component  (PC)
scores plot of the first two principal components (PC1 and
PC2) to provide the most efficient 2D representation of the
information  contained  in  the  data  set,  where  each  point
represents an individual spectrum of a sample.
Statistics: Data were presented as means±SD. The results
were analyzed by the ANOVA (ANOVA, SPSS 11.5, SPSS
Inc., Chicago, IL). The difference was considered significant
when p<0.05.
RESULTS
General condition: The eyes were examined by means of the
slit lamp and indirect ophthalmoscope during the follow-up.
No retinal detachment and endophthalmitis were noted in the
experimental eyes. No apparent abnormality was found in
blood pressure and blood biochemistry test.
IOP: There were no significant differences in IOP in any of
the groups pre-injection (p>0.05). IOP in the GL group was
lower than that in the control group during the follow-up
(p<0.05). Significant elevation of IOP was noticed in the TA
group at 1, 7, 14, 21, and 28 days post-injection, compared to
the controls (p<0.01). IOP in the TA+GL group was lower
than that in the TA group during the follow-up (p<0.01),
except  at  1  day  post-injection  (p=0.602).  There  were  no
significant differences in IOP between the TA+GL group and
the GL+TA group in the follow-up (p>0.05), except higher
IOP was recorded in the TA+GL group at 1 day post-injection
(p=0.004). The IOP changes in this experiment are shown in
Table 1.
Flash ERG and flash VEP: No significant differences in IT or
amplitudes were found in any of the groups pre-injection
(p>0.05). In flash ERG, the amplitudes were decreased, and
IT  was  prolonged  in  the  TA  group  during  the  follow-up,
compared  to  the  controls  (p<0.05).  The  amplitudes  were
increased, and IT was decreased in the TA+GL group and the
GL+TA group during the follow-up, compared to the TA
group  (p<0.05).  There  were  no  significant  differences
between the TA+GL group and the GL+TA group in the
follow-up  (p>0.05).  In  flash  VEP,  the  amplitudes  were
decreased, and IT was prolonged in the TA group at 28 days
post-injection,  compared  to  the  controls  (p<0.05).  The
amplitudes of the TA+GL group and the GL+TA group were
higher, and IT was lower than those in the TA group at 28 days
post-injection (p<0.05). There were no significant differences
between the TA+GL group and the GL+TA group (p>0.05).
Flash ERG and flash VEP changes in this experiment are
shown in Table 2, Table 3, and Table 4.
NMR spectroscopy: A total of 18 metabolites, based on their
characteristic  chemical  shifts  and  multiplicities,  were
identified in 1H-NMR spectrum within the region from 0 to 9
ppm. Those metabolites included isoleucine, leucine, valine,
alanine, lactate, acetate, glutamine and glutamate complex
(Glx),  citrate,  trimethyamine,  creatine,  N-
acetylglycoproteins, choline, taurine, glycerol, glucose, fatty
acid (low density lipoprotein, very low density lipoprotein)
and formate. Typical 1H-NMR spectrum of aqueous humor
was shown in Figure 1.
PCA: No significant differences in metabolites were found in
any of the groups pre-injection.
The  concentration  of  12  metabolites  (low  density
lipoprotein, very low density lipoprotein, isoleucine, leucine,
TABLE 1. IOP CHANGES IN RABBITS AFTER ADMINISTRATION OF GL (MM HG).
Group division Pre 1d p 7d p 28d p
Control 15.5±2.3 16.2±2.4 <0.001 15.8±2.2 <0.001 16.4±2.9 0.035
GL 15.8±3.2 15.4±4.5 <0.001 14.6±3.6 <0.001 15.1±3.1 <0.001
TA 15.7±2.8 37.3±3.7 0.602 39.4±3.5 <0.001 37.5±3.8 <0.001
TA+GL 15.4±2.6 38.5±2.7   28.2±5.6   26.8±6.3  
GL+TA 15.7±3.5 30.1±4.9 0.004 27.3±4.7 0.523 26.1±5.7 0.782
               p, the p-value (ANOVA) when the TA+GL group was compared to other groups.
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choline,  taurine,  glycerol  and  glucose  decreased)  were
significantly changed in the aqueous humor of NZWR in the
TA group at 1 day after intravitreal injection, compared to the
controls.  Six  significantly  changed  metabolites  (alanine,
lactate, acetate, taurine, glycerol and glucose) were found in
the TA group at 28 days post injection, compared to the
controls. Compared the NMR spectrum in the TA group at 1
day with 28 days, seven metabolites (low density lipoprotein
and very low density lipoprotein decreased; alanine, lactate,
taurine, glycerol and glucose increased) were changed.
There  were  7  changed  metabolites  (lactate,  choline,
taurine and glucose increased; low density lipoprotein, very
low density lipoprotein and N-acetylglycoproteins decreased)
in the aqueous humor of NZWR in the TA+GL group and the
GL+TA group at 1 day post-injection, compared to the TA
group. The same metabolic changes were found in the TA+GL
group and the GL+TA group at 28 days post-injection, except
N-acetylglycoproteins.
There were no significant metabolites changes between
the GL+TA group and the TA+GL group, except higher levels
of lactate and glucose in the GL+TA group at 1 day post-
injection.
TABLE 2. AMPLITUDES OF FLASH ERG IN RABBITS AFTER ADMINISTRATION OF GL (ΜV).
Group division Time Rod-R Max-R OPS Cone-R 30 Hz-F
    b wave a wave b wave total a wave b wave Amp
Control
  Pre 182.4±31.3 100.6±23.3 220.6±37.1 156.7±30.3 27.4±4.2 105.6±22.1 31.6±5.4
  7d 177.4±29.4 97.3±22.5 215.1±30.6 152.3±27.6 26.5±5.1 100.3±23.1 30.7±6.3
  28d 174.6±33.3 95.0±20.8 212.4±43.7 149.4±26.9 24.9±5.6 96.2±25.8 28.8±4.7
 
Pre 180.3±40.1 102.4±34.2 224.3±32.5 153.2±36.2 26.9±3.7 104.1±24.3 31.4±4.8
GL
  7d 174.6±31.5 99.2±23.4 218.1±37.4 152.6±24.8 26.5±4.3 101.2±26.7 30.2±5.9
  28d 172.7±34.1 97.4±21.2 213.2±36.8 150.3±28.6 25.3±4.4 98.4±24.5 27.9±3.2
TA
  Pre 186.4±34.5 98.1±25.9 226.7±36.3 160.2±28.3 26.4±4.6 102.6±28.7 32.8±5.6
  7d 158.4±27.2 82.4±21.7 200.6±32.7 140.9±25.2 21.9±3.6 84.6±20.3 27.7±5.1
  28d 152.2±28.3 79.7±19.2 190.4±28.6 133.7±29.3 19.7±3.7 79.2±19.3 24.9±4.3
TA+GL
  Pre 189.4±35.2 96.5±24.6 225.6±44.2 162.4±32.5 27.9±4.9 100.4±29.5 31.2±5.3
  7d 179.3±22.2** 94.7±25.4** 221.5±38.3** 158.5±19.3** 25.8±3.9** 95.3±24.8** 30.5±6.4**
  28d 164.2±19.8* 86.3±18.6* 203.9±37.4* 140.8±24.2* 22.5±4.8* 89.0±26.8* 26.3±3.7*
GL+TA
  Pre 186.1±33.2 95.1±34.5 222.7±41.6 163.3±36.9 27.2±4.7 101.5±26.3 30.8±6.4
  7d 176.2±31.2** 96.3±22.2** 218.4±35.6** 157.3±21.8** 26.1±3.6** 96.4±22.7** 30.8±5.3**
  28d 165.7±23.2* 89.6±20.6* 205.7±35.2* 143.6±25.4* 22.9±3.3* 88.1±24.7* 25.8±3.6*
         *, p<0.05 (ANOVA) when the TA group compared to other groups. **, p<0.01 (ANOVA) when the TA group was compared
         to other groups.
TABLE 3. IMPLICIT TIME OF FLASH ERG IN RABBITS AFTER ADMINISTRATION OF GL (MS).
ERG parameters Control TA TA+GL
  Pre 7d 28d Pre 7d 28d Pre 7d 28d
Rod-R 46.3±4.8 46.7±4.2 47.2±3.9 46.4±3.3 50.2±4.3 50.7±4.5 45.2±3.7 45.9±4.4** 48.8±3.8*
Max-R 38.1±5.2 38.7±4.9 39.2±4.3 38.5±4.2 42.8±5.3 43.1±2.3 37.8±3.5 38.2±4.1** 40.9±5.7*
Cone-R 27.8±3.7 28.4±4.2 28.6±3.1 27.5±4.7 33.2±4.6 34.0±4.7 27.6±3.6 27.7±4.4** 31.2±4.9*
         *, p<0.05 (ANOVA) when the TA+GL group compared to other groups. **, p<0.01 (ANOVA) while the TA+GL group
         compared to the TA group.
TABLE 4. AMPLITUDES (BASELINE=100) AND IMPLICIT TIME (MS) OF FLASH VEP IN RABBITS AFTER ADMINISTRATION OF GL.
VEP parameters Control TA TA+GL
  Pre 7d 28d Pre 7d 28d Pre 7d 28d
IT 24.9±2.6 24.2±3.2 25.5±3.9 25.2±3.6 25.0±3.4 27.6±3.8** 24.6±3.1 24.9±2.9 26.8±2.3*
Amplitude 100 93.2±18.9 104.7±14.3 100 92.7±15.8 77.2±13.4** 100 96.3±14.8 89.7±13.6*
         *, p<0.05 (ANOVA) when the TA+GL group compared to other groups. **, p<0.01 (ANOVA) when the TA group compared
         to the control group.
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DISCUSSION
Glycyron is a first-line drug for hepatic cirrhosis and other
liver diseases, with little side effects. Each tablet contains
25 mg GL and Supplemental Materials (25 mg glycine and
25 mg D-L-methionine). And in this experiment, it showed no
side  effects  in  the  rabbits  by  blood  pressure  and  blood
biochemistry testing.
The ocular hypotensive effects of GL on a rabbit model
with OH were evaluated in this experiment. Our data showed
that IOP in the TA+GL group and the GL+TA group was
significantly  lower  than  that  in  the  TA  group.  Both  GL
pretreatment and post-treatment had the same hypotensive
effects, except that GL pretreatment had better IOP control at
1 day after intravitreal TA. Those results indicated that IOP
could  be  reduced  by  using  GL.  But  even  with  the
administration of GL, IOP was still higher than the controls.
That  result  may  be  associated  with  these  factors:  1)  GL
dosage; The usually used dosage for adults was 2 or 3 tablets
per time and 3 times per day (150–225 mg GL per day). In
this study, the dosage for rabbits is half tablet per time and 2
times per day (25mg GL per day). That dosage was calibrated
on the comparison of body surface (rabbit versus human). But
the rabbits could only receive two feedings per day according
to their habits, not like human (three times per day). That
difference may bring about insufficient GL concentration in
ocular tissue. 2) TA dosage: The appropriate TA dosage for
rabbit is 0.1ml/1.3 mg [28]. The high dosage we used here was
just to make OH models. Even IOP in the GL-treated groups
was lower than that in the TA group during the follow-ups; it
was still higher than the controls. This result suggested that
GL could not inhibit TA-induced OH completely because of
the high TA dosage. 3) Species difference; Despite NZWR is
a suitable model for 11β-HSD1 study, the species difference
may affect the susceptibility to GL.
ERG  represents  the  general  function  of  the  retina,
especially the function of the photoreceptor and bipolar cells.
Scotopic ERG mainly expresses the function of the rod cells,
and photopic ERG expresses the cone cells. VEP response
represents the general function of the optic nerve. In this study,
the amplitudes were decreased and IT was prolonged in the
TA group both in flash ERG and VEP during the follow-up,
which  indicated  the  retinal  and  optic  nerve  function  was
impaired. GL intervention had a protective effect resulted in
better  parameters  in  electrophysiology,  which  may  also
contribute to 11β-HSD1 inhibition.
The metabolism is necessary to maintain biologic activity
of the cells (e.g., signaling and energy transferring between
the cells). So the external influences (nutrition, drug, etc.) on
cells can be better evaluated by analyzing their metabolites
[23,25,26].  The  pathogenesis  of  CIG/OH  still  remains
unclear, but it is certainly in connection with glucocorticoid
metabolism.  So  we  used  metabolomics  here  to  study  the
glucocorticoid effects on ocular metabolism.
Compared  to  the  controls,  the  significantly  changed
metabolites in the TA group at 1 day post-injection (represents
the acute reaction phase after injection) are as follows: lipid
(low  density  lipoprotein,  very  low  density  lipoprotein,
choline, and glycerol), protein (isoleucine, leucine, valine, and
Figure 1. Typical 600 MHz  1H-NMR
spectrum (0–9 ppm) of rabbit aqueous
humor from the TA+GL group (one day
post-injection).
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2061alanine), sugar (lactate, acetate, and glucose), acute phase
protein (N-acetylglycoproteins) and anti-oxidant (taurine). At
28 days post-injection (represents the chronic reaction phase
after  injection),  the  changed  metabolites  included  lipid
(glycerol),  protein  (alanine),  sugar  (lactate,  acetate,  and
glucose), and anti-oxidant (taurine). Those data showed that
TA  could  alter  ocular  metabolism  in  a  time-dependant
manner. Analyzed by PCA (Figure 2), the major biochemical
difference between the TA group and the controls is that TA
affects sugar metabolism, especially suppresses tricarboxylic
acid cycle. That effect could lead to higher glucose level in
aqueous  humor,  which  could  induce  more
mucopolysaccharide and fibronectin deposition in trabecular
meshwork to reduce aqueous outflow [29-31]. This is the first
time to announce that suppressed tricarboxylic acid cycle is
the major biochemical reaction of CIG/OH.
Compared to the TA group, the changed metabolites in
the TA+GL group and the GL+TA group post-injection are as
follows: lipid (low density lipoprotein and very low density
lipoprotein  and  choline),  anti-oxidant  (taurine)  and  sugar
(lactate and glucose). The major biochemical change is that
TA-induced effect (tricarboxylic acid cycle suppression) was
partly  inhibited  by  GL  intervention.  All  those  changed
metabolites are closely related to pathogenesis of glaucoma:
low density lipoprotein can induce mRNA overexpression of
fibronectin, α-laminin and collagen type IV, all of which are
participated in CIG pathogenesis [32]. Lactate is essential to
ATP production and is important to excitatory neurons [33],
the  deposition  of  lactate  represents  that  the  neurons  are
damaged  because  of  ischemia  [34].  Choline  is  a  key
component of lecithin and sphingomyelin, and is useful in
glaucoma treatment. Parisi et al. [35,36] treated glaucoma
patients with citicoline and found that ERG and VEP was
improved. That finding is also supported by other studies
[37-40]. In this study, all those metabolites were significantly
changed  after  administration  of  GL,  which  maybe  is  the
metabolic mechanism of GL hypotensive effects.
Figure 2. The confidence ellipse of PCA
scores plots. A: PCA scores plots of 1H-
NMR spectrum between the TA group
(◇) and the TA+GL group (■), one day
post-injection. B: PCA scores plots of
1H  NMR  spectrum  between  the  TA
group (◇) and the TA+GL group (◇),
28 days post-injection.
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206211β-HSD1 is regarded as a potential target to regulate GC
activity. In this experiment, GL, an inhibitor of 11β-HSD, was
administrated in the TA-induced OH rabbits. Our data showed
that GL could significantly decrease IOP in OH cases. The
metabolomics  study  indicated  that  GL  could  affect  TA-
induced ocular metabolism. So according to our results, we
hypothesized the following possible mechanism: TA could
induce the changes of ocular metabolism, which may cause
IOP elevation. GL, an inhibitor of 11β-HSD1, may block the
excess production of cortisol by binding 11β-HSD1. Thus it
could decrease IOP by compensating the changes of TA-
induced  ocular  metabolism.  Further  studies  in  molecular
biology are needed to prove that hypothesis.
11β-HSD2 was found in corneal endothelium or non-
pigmented epithelium (NPE) of the ciliary body, while the
mineralocorticoid receptor was present in the NPE cell line
[18,41].  Those  findings  suggested  that  11beta-HSD2  may
play an important role in producing aqueous humor. Glycyron
is a non-specific inhibitor of the 11β-HSDs, so the type 2
enzyme in the ocular tissue is also inhibited in this study. This
isozyme protects the mineralocorticoid receptor from cortisol
excess  [42].  Switching  off  11β-HSD2  could  result  in  the
changes in extracellular sodium, which may increase the IOP.
The IOP changes after GL administration were depended on
the overall effects of 11β-HSD1 versus 11β-HSD2: If 11β-
HSD1 inhibition was stronger than 11β-HSD2 inhibition, the
IOP would decrease, vice versa. Our results (IOP in the GL
group was lower than the controls) suggested that 11β-HSD1
inhibition was stronger than 11β-HSD2 ones.
In a conclusion, the administration of GL could suppress
OH induced by TA in rabbits (GL pre-treatment has better IOP
control), and improve their electrophysiological parameters.
Metabolomics is a useful tool in ophthalmology research. Our
results indicate that TA-induce ocular metabolism changes
could be compensated by GL.
We also acknowledge that there exists the potential for
misleading conclusions, because the number of rabbits and the
range of dosage are limited. And the molecule mechanisms
still remain unclear. Further investigations are necessary to
determine the efficacy of GL.
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